---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-221213"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:47:11.535375+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Forte Q2 net loss $3.0M; cash $38.5M; FB-102 on track for late 2023/early 2024

## Summary
- Net loss $3.0M for Q2 2022 ($0.21 per share), compared to $5.8M loss ($0.43) in Q2 2021.
- Cash and equivalents $38.5M as of June 30, 2022; raised $7.0M via ATM in July/August.
- R&D spend down to $1.0M from $3.5M YoY as FB-401 wound down; focus shifting to autoimmune pipeline.
- Lead candidate FB-102 expected to enter clinic late 2023 or early 2024 for GvHD, vitiligo, alopecia areata.
- Appointed Hubert Chen as CSO and President; added Stephen Doberstein to board of directors.

## SEC filing metadata
- accession: 0001193125-22-221213
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312522221213/0001193125-22-221213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312522221213/d303551d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-221213
- JSON: https://secwatch.observer/filing/0001193125-22-221213.json
- Plain text: https://secwatch.observer/filing/0001193125-22-221213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.